GO-Y078

GO-Y078 (1-16 μM; 24 h) reduces the viability of osteosarcoma U2OS, MG-63, 143B and Saos-2 cells in a dose-dependent manner. After 24 h of treatment, the inhibitory effect is the strongest at the concentration of 16 μM (the viability of U2OS cells decreases by 54.7%, that of MG-63 cells by 79.6%, that of 143B cells by 58.9%, and that of Saos-2 cells by 71.6%)^[1].
GO-Y078 (2.5-40 μM; 24 h) inhibits the viability of cervical squamous cell carcinoma SiHa cells and cervical adenocarcinoma HeLa cells, with an IC₅₀ of 7.76 μM for the former and 11.94 μM for the latter^[2].
GO-Y078 (0.5-4 μM; 24 h) potently inhibits the viability of SCC-9 and HSC-3 oral squamous cell carcinoma cells, with an IC₅₀ of <4 μM, and exhibits stronger cytotoxic potency than DMC^[3].
GO-Y078 (1-8 μM; 24 h) induces sub-G1 phase cell cycle arrest in osteosarcoma U2OS and 143B cells. After treatment with 8 μM for 24 h, the proportion of sub-G1 phase cells increases to 24.3% in U2OS cells and to 26.9% in 143B cells^[1].
GO-Y078 (1-8 μM; 24 h) induces apoptosis in osteosarcoma U2OS and 143B cells in a dose-dependent manner. After 24 h of treatment, the proportion of Annexin V-positive cells increases to approximately 35% in U2OS cells and to approximately 50% in 143B cells at the concentration of 8 μM^[1].
GO-Y078 (1-8 μM; 24 h) reduces the expression of anti-apoptotic proteins cIAP-1 and XIAP in osteosarcoma U2OS and 143B cells in a dose-dependent manner, while upregulating the level of pro-apoptotic activated caspase-3 in U2OS cells after 24 h of treatment^[1].
GO-Y078 (1-8 μM; 24 h) activates the ERK1/2, JNK1/2 and p38 MAPK signaling pathways in osteosarcoma U2OS and 143B cells in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.